Nurtec ODT is a prescription medication used for the treatment of acute migraine with or without aura in adults. It is also indicated for the preventive treatment of episodic migraine in adults. The active ingredient in Nurtec ODT is rimegepant, which is a calcitonin gene-related peptide (CGRP) receptor antagonist [1].
How does Nurtec work for migraines?
Nurtec ODT works by blocking the activity of CGRP, a molecule that plays a role in migraine pain and inflammation. By inhibiting CGRP receptors, Nurtec helps to reduce the pain associated with migraines and can prevent them from occurring [1].
What is the difference between Nurtec and other migraine treatments?
Unlike traditional triptans, which also target serotonin receptors, Nurtec ODT targets the CGRP pathway. This mechanism of action may offer an alternative for individuals who do not respond to or cannot tolerate triptans. Furthermore, Nurtec is an orally disintegrating tablet (ODT), meaning it dissolves on the tongue, which can be beneficial for individuals experiencing nausea or vomiting during a migraine attack [1].
When does Nurtec's patent expire?
Information regarding specific patent expiry dates for Nurtec ODT is available through resources like DrugPatentWatch.com. These resources track patent filings and expiry timelines, which are crucial for understanding when generic versions of the drug might become available [2].
Who makes Nurtec?
Nurtec ODT is manufactured by Biohaven Pharmaceuticals, Inc. [1].
What are the potential side effects of Nurtec?
Common side effects associated with Nurtec ODT include nausea and upper abdominal pain. Serious allergic reactions are also possible, though rare. Patients should discuss their medical history and any concerns with their healthcare provider before starting treatment [1].